COVID Vaccines/Therapeutics – Developer/Manufacturer Announcements
[Selected press releases/announcements from organizations from WHO EUL/PQ listing above and other organizations]

AstraZeneca
Press Releases – No new digest announcements identified
 
Bharat Biotech
Press Releases – No new digest announcements identified

BioCubaFarma – Cuba
Últimas Noticias – Website not leading at inquiry

Biological E
News – No new digest announcements identified

Biontech
Press Releases– No new digest announcements identified
CanSinoBIO
News – Website not responding at inquiry

CIGB
Latest News
Purity and efficacy of Mambisa, the first anti-covid nasal vaccine (Part II)
Interview
06 de mayo de 2022

Cinagen
Recent News– No new digest announcements identified

Clover Biopharmaceuticals – China
News
May 5, 2022
Clover’s Bivalent COVID-19 Vaccine Candidate Demonstrates Broad Neutralization Against Omicron and Other Variants of Concern
— Bivalent candidate (Prototype + Omicron) demonstrates broad neutralization against Omicron and all VoCs in both primary vaccination and booster settings in preclinical study
— Potential to pursue licensure pathway based on immuno-bridging to prototype vaccine candidate SCB-2019 (CpG 1018/Alum) which utilizes the validated Trimer-Tag™ technology platform

Curevac [Bayer Ag – Germany]
News – No new digest announcements identified

Gamaleya National Center
Latest News and Events – See Russia below.

IMBCAMS, China
Home – Website not responding at inquiry

Janssen/JNJ
Press Releases – No new digest announcements identified

Medicago
Media
May 5, 2022
Medicago announces publication of Phase 3 COVID-19 vaccine study results in New England Journal of Medicine
Study results were included in the submission to Health Canada leading to Notice of Compliance

Moderna
Press Releases – No new digest announcements identified

Nanogen
News – No new digest announcements identified

Novavax
Press Releases
May 6, 2022
Statement
Novavax Submits Variations to Expand Australian and New Zealand Provisional Approval of Nuvaxovid™ COVID-19 Vaccine to Adolescents aged 12 Through 17 Years

May 6, 2022
Statement
Novavax’ COVID-19 Vaccine Nuvaxovid™ Arrives in Singapore

May 4, 2022
Statement
Novavax Requests Expanded Authorization of Nuvaxovid™ COVID-19 Vaccine to Adolescents Aged 12 through 17 Years in Great Britain*

Pfizer
Recent Press Releases – No new digest announcements identified

R-Pharm
https://rpharm-us.com/index.php
[No news or media page identified]

Sanofi Pasteur
Press Releases – No new digest announcements identified

Serum Institute of India
NEWS & ANNOUNCEMENTS – No new digest announcements identified

Shifa Pharmed [Iran]
http://shafapharmed.com/
No news page identified.

Sinopharm/WIBPBIBP
News – No new digest announcements identified

Sinovac
Press Releases
China NMPA approved SINOVAC Omicron-specific vaccine for clinical trial
2022/04/26

Vector State Research Centre of Viralogy and Biotechnology
Home – No new digest announcements identified [404 error]

WestVac Biopharma
Media – No new digest announcements identified

Zhifei Longcom, China
[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]
[No website identified]

::::::

GSK
Press releases for media – No new digest announcements identified

Merck
News releases – No new digest announcements identified

Novartis
News – No new digest announcements identified

SK Biosciences
Press Releases – No new digest announcements identified

Valneva
Press Releases
Valneva Initiates Heterologous Booster Trial of Inactivated, COVID-19 Vaccine Candidate
Saint-Herblain (France), May 4, 2022 – Valneva SE, a specialty vaccine company, today announced the initiation of a heterologous booster trial of its inactivated whole-virus COVID-19 vaccine candidate VLA2001. The VLA2001-307 trial will be the Company’s first clinical trial to provide booster data following primary vaccination with an mRNA vaccine or natural COVID-19 infection…